结核病患者N-乙酰基转移酶2基因型与异烟肼血药浓度关系的研究

中国防痨杂志 ›› 2013, Vol. 35 ›› Issue (3): 179-182.

结核病患者N-乙酰基转移酶2基因型与异烟肼血药浓度关系的研究

刘诚诚金海霞徐建李华朱慧付雷王彬陆宇

101149 北京市结核病胸部肿瘤研究所首都医科大学附属北京胸科医院药物研究室（刘诚诚、金海霞、徐建、朱慧、付雷、王彬、陆宇），结核内科（李华）

收稿日期:2012-12-07 出版日期:2013-03-10 发布日期:2013-03-14
通信作者: 陆宇 E-mail:luyu4876@hotmail.com
基金资助:
北京市优秀人才培养基金(2011D003034000005)

The relationship between N-acetyltransferase 2 genotypes and the concentration of isoniazid in human plasma

LIU Cheng-cheng, JIN Hai-xia, XU Jian, LI Hua, ZHU Hui, FU Lei, WANG Bin, LU Yu

Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Department of Pharmacology, Beijing 101149, China

Received:2012-12-07 Online:2013-03-10 Published:2013-03-14
Contact: LU Yu E-mail:luyu4876@hotmail.com

摘要/Abstract

摘要： 目的探讨结核病患者N-乙酰基转移酶2(NAT2)基因型与异烟肼(INH)血药浓度的关联性，为临床根据NAT2基因分型指导合理INH用药提供依据。方法应用PCR结合限制性片段长度多态性（PCR-RFLP）方法对121例住院结核病患者NAT2基因型分布进行检测，同时应用液相色谱-串联质谱分析仪（LC/MS-MS）检测结核病患者服药2h后血浆INH浓度。所获数据采用单因素方差分析检测组间差异，进而采用Tamhane’s T2法进行两两比较，以P＜0.05为差异有统计学意义。结果 121例结核病患者NAT2基因型中快速乙酰化型（RA，野生型）有55例，INH血药浓度为（1.86±1.28）μg/ml；慢乙酰化型（SA，纯合突变型）有17例，INH血药浓度为（5.86±2.10）μg/ml；中间乙酰化型（IA，杂合突变型）有49例，INH血药浓度（3.49±2.60）μg/ml。住院结核病患者整体INH血药浓度均值为（3.08±2.42）μg/ml。三型INH血药浓度比较，差异均具有显著统计学意义（RA与IA，P＝0.001；RA与SA，P＝0.002；IA与SA，P＝0.000）。结论不同NAT2基因型人群对INH的代谢能力差异存在显著统计学意义，NAT2基因型分析对结核病患者INH用药具有重要指导意义。

关键词: 结核,肺, 芳基胺N-乙酰转移酶, 异烟肼, 基因型, 血药浓度

Abstract: Objective To study the correlation between N-acetyltransferase 2 (NAT2) genotypes and the concentration of isoniazid (INH) in the plasma, and provide a theoretical basis for the individualized medication of tuberculosis (TB) patients by NAT2 genotyping. Methods The NAT2 genotypes of 121 TB patients were analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). INH concentration in the plasma was detected by the liquid chromatography-tandem mass spectrometry (LC/MS-MS) at 2 hours after treatment. The differences between the groups were tested by using single factor analysis of variance, and then the differences of every two groups were tested by using Tamhane’s T2, P＜0.05 was considered statistically significant. Results Of 121 TB patients, 55 were NAT2 rapid acetylation (RA) type，and their average concentration of INH in plasma was（1.86±1.28）μg/ml; 17 were slow acetylation (SA) type (homozygous mutant), their INH concentration was（5.86±2.10）μg/ml; 49 were intermediate acetylation (IA) type (heterozygous mutant), and the INH concentration was（3.49±2.60）μg/ml. INH concentration of hospitalized TB patients in plasma was（3.08±2.42）μg/ml. INH concentration among the three groups have statistically significant differences (RA with IA, P＝0.001；RA with SA，P＝0.002; IA with SA，P＝0.000，P＜0.05). Conclusion There were significant differences among the TB patients with different NAT2 genotypes. NAT2 genotyping has important guiding significance for the INH treatment in the TB patients.

Key words: Tuberculosis, pulmonary, Arylamine N-acetyltransferase, Isoniazid, Genotype, Plasma concentration

刘诚诚金海霞徐建李华朱慧付雷王彬陆宇. 结核病患者N-乙酰基转移酶2基因型与异烟肼血药浓度关系的研究[J]. 中国防痨杂志, 2013, 35(3): 179-182.

LIU Cheng-cheng, JIN Hai-xia, XU Jian, LI Hua, ZHU Hui, FU Lei, WANG Bin, LU Yu. The relationship between N-acetyltransferase 2 genotypes and the concentration of isoniazid in human plasma[J]. Chinese Journal of Antituberculosis, 2013, 35(3): 179-182.

参考文献

［1］World Health Organization. Tuberculosis facts 2009 update［EB/OL］. (2009-12-09) ［2010-03-18］.http://www.who.in/tb/publications/2009/factsheet＿tb＿2009update＿dec09.pdf.

［2］任晓波，吴平，李莉，等.结核病的发病趋势及健康教育.家庭护士,2007,5(10):78-79.

［3］Ray J, Gardiner I, Marriott D.Managing antituberculosis drug therapy by therapeutic drug monitoring of rifampicin and isoniazid．Intern Med J,2003,33(5/6):229-234．

［4］Hein DW，Doll MA, Fretland AJ,et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms.Cancer Epidemiol Biomarkers Prev,2000,9(1)：29-42．

［5］Zang Y，Doll MA,Zhao S，et a1．Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2．Carcinogenesis，2007,28(8)：1665-1671．

［6］Cascorbi I, Drakoulis N, Brockmoller J, et al．Arylamine N-acetyltransferase(NAT2) mutations and their allelic linkage in unrelated Caucasian individuals：correlation with phenotypic activity．Am J Hum Genet，1995，57(3)：581-592．

［7］Blum M，Demierre A，Grant DM，et al．Molecular mechanism of slow acetylation of drugs and carcinogens in humans．Proc Natl Acad Sci U S A,1991，88(12)：5237-5241．

［8］Deloménie C, Sica L, Grant DM, et al.Genotyping of the polymorphic N-acetyltransferase(NAT2*) gene locus in two native African populations. Pharmacogenetics,1996,6(2):177-185.

［9］Fukino K, Sasaki Y, Hirai S, et al.Effect of N-acetyltransferase 2(NAT2),CYP2E1 and Glutathione-S-transferase(GST) genotype on the serum concentrations of isoniazid and metabolites in tuberculosis patients. J Toxicol Sci, 2008, 33（2）:187-195.

［10］中华医学会结核病学分会.肺结核诊断和治疗指南.中华结核和呼吸杂志，2001,24（2）:70-74.

［11］Lin HJ, Han CY, Lin BK, et al. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites: application to metabolic epidemiology. Am J Hum Genet, 1993, 52(4):827-834.

［12］Takakubo F, Yamamoto M, Ogawa N, et al. Genetic association between cytochrome P450IA1 gene and susceptibility to Parkinson’s disease. J Neural Transm, 1996, 103 (7):843-849.

［13］陈冰，李金恒，黄晶，等. 一步等位基因特异扩增法检测中国人N-乙酰化酶基因型. 中国临床药理学杂志，2004,20（1）：49-52.

[1]	梁小烟, 林玫, 梁大斌, 蓝如束, 覃慧芳, 叶婧, 黄莉雯. 广西壮族自治区耐多药结核分枝杆菌耐药情况与基因型特征分析[J]. 中国防痨杂志, 2020, 42(6): 578-582.
[2]	洪创跃, 杨婷婷, 李金莉, 李霜君, 吴利凯, 杨争, 谭卫国. 深圳市耐多药结核分枝杆菌耐药基因突变特征分析[J]. 中国防痨杂志, 2020, 42(6): 583-589.
[3]	赵皎洁,付雷,王彬,张蕾,胡明豪,陆宇. 抗结核药物体外药代动力学/药效学研究模型的建立及应用[J]. 中国防痨杂志, 2020, 42(4): 372-379.
[4]	宋艳华,高孟秋,李琦. 结核分枝杆菌对乙硫异烟胺/丙硫异烟胺耐药的机制及其增敏剂研究进展[J]. 中国防痨杂志, 2020, 42(2): 173-177.
[5]	买买提艾力·艾合木提, 黄巧玲, 古尔色曼·阿布拉, 热纳提·艾来提. 新疆喀什地区1307例肺结核患者行利福平和异烟肼耐药性检测的结果分析[J]. 中国防痨杂志, 2020, 42(11): 1209-1213.
[6]	张满娥,黄文滨,卢志华,张洪彬. 福建省龙岩市411例肺结核患者对利福平和异烟肼耐药状况的研究[J]. 中国防痨杂志, 2020, 42(1): 54-59.
[7]	刘元,周俊,崔晓利,雷佳媛,党丽云. 基因芯片与线性探针技术检测涂阳肺结核患者痰标本MTB耐药性的价值[J]. 中国防痨杂志, 2019, 41(7): 738-742.
[8]	刘晓俊,余枫华,余云芳,纪律,周攀,赵雁林. 宜昌地区结核分枝杆菌基因分型与成簇特征分析[J]. 中国防痨杂志, 2019, 41(3): 308-314.
[9]	彭英,唐鹭,裴新发,张学志,林百丰,陈丽,于艳玲,李发滨. 黑龙江省五常市结核分枝杆菌基因型及传播特征[J]. 中国防痨杂志, 2019, 41(3): 315-321.
[10]	谢彤,王春花,赵慧,巨韩芳,穆成,王志锐,孙蕊. 天津市监狱羁押人员中结核病患者临床分离菌株的基因型分析[J]. 中国防痨杂志, 2019, 41(3): 361-363.
[11]	白雪娟,刘银萍,张俊仙,王杰,吴雪琼. 应用基因芯片直接检测结核病患者各类标本中利福平和异烟肼耐药的价值[J]. 中国防痨杂志, 2019, 41(2): 138-144.
[12]	江丽娜,穆成,孙蕊,王志锐,戴文汐,王春花. 二代线性探针技术在结核分枝杆菌耐药性检测中的价值[J]. 中国防痨杂志, 2019, 41(11): 1184-1190.
[13]	吴慧娜,孙付胜,刘清文,戎中录,张纪东,高阳,李永福,常斐. 荧光PCR探针熔解曲线法检测结核分枝杆菌复合群对利福平和异烟肼耐药性的价值[J]. 中国防痨杂志, 2019, 41(1): 74-79.
[14]	刘艳,古丽比克·木拉提,玛力亚木·阿布力提甫,易星,李君莲,师永欢,刘天剑. 荧光PCR熔解曲线法检测结核分枝杆菌耐药基因的结果分析[J]. 中国防痨杂志, 2018, 40(9): 959-963.
[15]	郭少晨,朱慧,郭超,王彬,刘忠泉,徐建,付雷,陈效友,陆宇. 909例结核病患者一线抗结核药物血药浓度监测结果分析[J]. 中国防痨杂志, 2018, 40(7): 744-749.